Boston Scientific Corporation (NYSE: BSX) today presented a four-year update of its key randomized, controlled clinical trials (TAXUS II, IV, V and VI) in 3,445 patients, comparing the TAXUS(R) stent to bare-metal control stents. Included in this number were 840 diabetic patients. [click link for full article]
More...